These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 38665131)
1. Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2. Sato R; Komatsuda H; Inoue T; Wakisaka R; Kono M; Yamaki H; Ohara K; Kumai T; Kishibe K; Hayashi T; Takahara M Head Neck; 2024 Sep; 46(9):2233-2243. PubMed ID: 38665131 [TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251 [TBL] [Abstract][Full Text] [Related]
3. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737 [TBL] [Abstract][Full Text] [Related]
4. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Okamoto I; Sato H; Tsukahara K Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271 [TBL] [Abstract][Full Text] [Related]
5. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025 [TBL] [Abstract][Full Text] [Related]
7. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE Front Immunol; 2019; 10():1644. PubMed ID: 31379843 [No Abstract] [Full Text] [Related]
9. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970 [TBL] [Abstract][Full Text] [Related]
10. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma. Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW Oncology; 2021; 99(7):464-470. PubMed ID: 33789303 [TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D; Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945 [TBL] [Abstract][Full Text] [Related]
13. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413 [TBL] [Abstract][Full Text] [Related]
14. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960 [TBL] [Abstract][Full Text] [Related]
15. Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study). Lorini L; Zigliani G; Morbini P; Salviato E; Piazza C; Battocchio S; Preda L; Benazzo M; Ravanelli M; Mattavelli D; Bossi P Oral Oncol; 2024 Oct; 157():106950. PubMed ID: 39038413 [TBL] [Abstract][Full Text] [Related]
16. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma. Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect. Lee J; Kim B; Jung HA; La Choi Y; Sun JM Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755 [TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894 [TBL] [Abstract][Full Text] [Related]
19. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080 [TBL] [Abstract][Full Text] [Related]
20. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]